Midostaurin: A New Oral Agent Targeting FMS‐Like Tyrosine Kinase 3‐Mutant Acute Myeloid Leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1875-9114|37|12|1586-1599

ISSN： 0277-0008

Source： PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol.37, Iss.12, 2017-12, pp. : 1586-1599

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 306-314

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 276-281

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-07 ,pp. : 6-10

Karger

Access to resources Recommend Favorite

Cup‐like blasts in acute myeloid leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 847-848

John Wiley & Sons Inc

Access to resources Recommend Favorite